Invention Grant
- Patent Title: Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate
-
Application No.: US16843832Application Date: 2020-04-08
-
Publication No.: US11246873B2Publication Date: 2022-02-15
- Inventor: Peter Schultz , Luke Lairson , Vishal Deshmukh , Costas Lyssiotis
- Applicant: The Scripps Research Institute , Novartis AG
- Applicant Address: US CA La Jolla; CH Basel
- Assignee: The Scripps Research Institute,Novartis AG
- Current Assignee: The Scripps Research Institute,Novartis AG
- Current Assignee Address: US CA La Jolla; CH Basel
- Agency: Kilpatrick Townsend & Stockton LLP
- Main IPC: A61K31/44
- IPC: A61K31/44 ; A61K31/445 ; A61K31/40 ; A61K31/35 ; A61K31/24 ; A61K31/135 ; A61K38/00 ; A61K31/5415 ; A61K31/439 ; A61K31/138 ; A61K31/137 ; A61K38/21 ; A61K39/395 ; A61K31/216 ; A61K31/46 ; A61K31/495
Abstract:
The present invention provides methods of inducing differentiation of oligodendrocyte progenitor cells to a mature myelinating cell fate with a neurotransmitter receptor modulating agent. The present invention also provides methods of stimulating increased myelination in a subject in need thereof by administering said neurotransmitter receptor modulating agent. Methods of treating a subject having a demyelinating disease using a neurotransmitter receptor modulating agent are also provided.
Information query
